The store will not work correctly when cookies are disabled.
5-(3-Methylbenzo[d]isoxazol-6-yl)-3-(5-methyloxazol-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
ID: ALA3716198
PubChem CID: 90110823
Max Phase: Preclinical
Molecular Formula: C18H13N5O3
Molecular Weight: 347.33
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5c(C)noc5c4)[nH]c23)o1
Standard InChI: InChI=1S/C18H13N5O3/c1-9-7-19-18(25-9)13-8-20-23-16(24)6-14(21-17(13)23)11-3-4-12-10(2)22-26-15(12)5-11/h3-8,21H,1-2H3
Standard InChI Key: NCYQZXXHOWLRKO-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 30 0 0 0 0 0 0 0 0999 V2000
0.2917 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 1.5132 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 -1.5132 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 -0.7475 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 -1.2033 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.5889 0.0182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 1.2033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9991 -2.7132 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.3751 3.8801 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.1749 2.6315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6243 2.9682 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.7308 4.4644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3406 5.0280 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0517 6.1927 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.6468 1.0526 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-8.5184 2.2403 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-7.6395 3.4592 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2188 2.9991 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2234 1.5040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9312 0.7344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6168 1.4950 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6117 2.9912 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9221 3.7609 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-8.0130 4.5996 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 1 0
1 6 1 0
7 8 2 0
8 9 1 0
6 7 1 0
1 9 2 0
5 10 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
11 15 1 0
15 16 1 0
9 12 1 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 1 0
17 21 1 0
22 23 1 0
23 24 2 0
24 25 1 0
20 25 2 0
21 22 2 0
19 26 1 0
3 23 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 347.33 | Molecular Weight (Monoisotopic): 347.1018 | AlogP: 3.10 | #Rotatable Bonds: 2 |
Polar Surface Area: 102.22 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 10.65 | CX Basic pKa: 0.82 | CX LogP: 1.08 | CX LogD: 1.08 |
Aromatic Rings: 5 | Heavy Atoms: 26 | QED Weighted: 0.53 | Np Likeness Score: -1.57 |
References
1. (2014) Heterocyclic compounds for the inhibition of pask, |
2. (2015) Heterocyclic compounds for the inhibition of pask, |